Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Operating Income (2016 - 2026)

Cumberland Pharmaceuticals' Operating Income history spans 16 years, with the latest figure at -$1.4 million for Q4 2025.

  • On a quarterly basis, Operating Income rose 25.56% to -$1.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$2.8 million, a 56.59% increase, with the full-year FY2025 number at -$2.8 million, up 56.59% from a year prior.
  • Operating Income hit -$1.4 million in Q4 2025 for Cumberland Pharmaceuticals, up from -$2.0 million in the prior quarter.
  • Over the last five years, Operating Income for CPIX hit a ceiling of $1.3 million in Q1 2025 and a floor of -$6.2 million in Q4 2023.
  • Historically, Operating Income has averaged -$1.6 million across 5 years, with a median of -$1.5 million in 2021.
  • Biggest five-year swings in Operating Income: tumbled 4591.4% in 2024 and later soared 169.12% in 2025.
  • Tracing CPIX's Operating Income over 5 years: stood at -$4.4 million in 2021, then surged by 47.68% to -$2.3 million in 2022, then crashed by 171.28% to -$6.2 million in 2023, then soared by 70.19% to -$1.8 million in 2024, then increased by 25.56% to -$1.4 million in 2025.
  • Business Quant data shows Operating Income for CPIX at -$1.4 million in Q4 2025, -$2.0 million in Q3 2025, and -$747478.0 in Q2 2025.